Tag Archive for: NEPC

Phase 1/2 Trial for MK-6070 (Gocatamig): A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers

MK-6070 (Gocatamig) is an engineered trispecific T-cell engager designed to target a protein called DLL3, which is predominantly found on certain aggressive neuroendocrine tumors, including prostate cancer. This molecule works by simultaneously binding to DLL3 on tumor cells, the CD3 receptor on T cells, and serum albumin, which extends the drug’s circulation time in the […]

Phase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer

NEPC

Preclinical: Targeting NSD2, a Promising Strategy Against Treatment-Induced Neuroendocrine Prostate Cancer